Neumora Therapeutics, Inc. (NMRA)

Market Cap	112.01M
Revenue (ttm)	n/a
Net Income (ttm)	-243.79M
Shares Out	161.75M
EPS (ttm)	-1.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,214,934
Open	0.6910
Previous Close	0.6629
Day's Range	0.6713 - 0.7697
52-Week Range	0.6210 - 17.1900
Beta	n/a
Analysts	Buy
Price Target	9.29 (+1,241.52%)
Earnings Date	May 12, 2025

About NMRA

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease. In a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 15, 2023
• Employees: 110
• Stock Exchange: NASDAQ
• Ticker Symbol: NMRA
• Website: https://www.neumoratx.com

Analyst Forecast

According to 8 analysts, the average rating for NMRA stock is "Buy." The 12-month stock price forecast is $9.29, which is an increase of 1,241.52% from the latest price.

Price Target

$9.29

(1,241.52% upside)

Analyst Consensus: Buy